Gilead’s partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries with rising HIV rates are excluded, and the control over the active pharmaceutical ingredient could delay price reductions. Patient groups are challenging Gilead’s patents globally, fearing the VL aims to maintain the company’s monopoly.
Related Posts
‘Cut your losers, let your winners ride…’: Zerodha’s Nithin Kamath shares risk management lesson amid market volatility
- staff
- March 17, 2025
- 0
Nithin Kamath stressed the importance of risk management for traders. He shared insights from successful traders, focusing on principles like reducing positions during drawdowns and […]
‘False’ FASTag wallet toll deduction? Here’s what NHAI is doing
- staff
- March 3, 2025
- 0
NHAI has imposed stringent measures against erroneous FASTag deductions, penalizing toll operators in about 250 cases. With a Rs 1 lakh fine for each violation, […]
Avaada Group to invest Rs 5,800 crore to develop 1200 MW pumped hydropower storage project in Rajasthan
Avaada Group will invest ₹5,800 crore to build a 1200MW pumped hydropower storage project in Rajasthan. The project, located in Sirohi district, aims to enhance […]